Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect

Shedding of ADAM10 substrates, like TNFa or CD30, can affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. We have published two new ADAM10 inhibitors, LT4 and MN8 able to prevent such shedding in Hodgkin lymphoma (HL). Since tumor tissue architecture deeply...

Descripción completa

Detalles Bibliográficos
Autores principales: Pece, Roberta, Tavella, Sara, Costa, Delfina, Varesano, Serena, Camodeca, Caterina, Cuffaro, Doretta, Nuti, Elisa, Rossello, Armando, Alfano, Massimo, D’Arrigo, Cristina, Galante, Denise, Ravetti, Jean-Louis, Gobbi, Marco, Tosetti, Francesca, Poggi, Alessandro, Zocchi, Maria Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968898/
https://www.ncbi.nlm.nih.gov/pubmed/34109776
http://dx.doi.org/10.3324/haematol.2021.278469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968898/
https://www.ncbi.nlm.nih.gov/pubmed/34109776
http://dx.doi.org/10.3324/haematol.2021.278469

Ejemplares similares